Welcome to our dedicated page for Enveric Biosciences SEC filings (Ticker: ENVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech report can feel like wading through lab notebooks. Enveric Biosciences’ 10-K details neuroplastogenic programs like EB-003, cash runway projections, and FDA correspondence—information scattered across hundreds of technical pages. If you have ever searched “understanding Enveric Biosciences SEC documents with AI,” you know the challenge.
Stock Titan simplifies the task. Our platform converts every Enveric Biosciences quarterly earnings report 10-Q filing, proxy statement executive compensation table, and 8-K material events into plain-English briefs. Interactive tools surface:
- Enveric Biosciences insider trading Form 4 transactions with real-time alerts
- Drug-development spend, trial milestones, and patent updates from the annual report 10-K simplified
- Fresh data on capital raises and collaboration agreements from 8-K material events explained
Whether you need an at-a-glance cash-to-completion estimate or want to track Enveric Biosciences executive stock transactions Form 4 before critical readouts, our AI highlights what matters. Each filing arrives moments after EDGAR posts, paired with contextual ratios, peer benchmarks, and keyword search so you can pivot from molecule to balance sheet in seconds.
Use this page to answer real investor questions, from “Where can I find the Enveric Biosciences earnings report filing analysis?” to “How is insider sentiment trending?” One click delivers every Enveric Biosciences Form 4 insider transactions real-time feed, every footnote on stock-based comp, and every risk-factor revision—organised, summarised, and searchable.
AdvisorShares Trust reported beneficial ownership of 203,679 shares of Enveric Biosciences, Inc. (ENVB), representing 6.27% of the outstanding common stock as of the 09/30/2025 event date. The filing is a Schedule 13G, indicating passive investment: the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing lists Stefanie Little, Chief Compliance Officer, as the signatory for AdvisorShares Trust and shows the trust is organized in Delaware. The reporting person has sole voting and sole dispositive power over the reported shares and reports no shared powers.
Enveric Biosciences, Inc. filed a Form D disclosing a Regulation D securities offering under Rule 506(b). The filing identifies the offering as indefinite with no proceeds sold to date and a first sale date of 2025-09-18. The securities offered are options/warrants to acquire common stock, issued as inducements to exercise previously issued warrants at a reduced price. The notice lists 12 current investors, reports estimated sales commissions of $155,321, and indicates $0 of gross proceeds have been used to pay executive officers or directors. The issuer is Enveric Biosciences, Inc., a Delaware corporation with corporate officers and directors based at 245 First Street, Cambridge, MA. H.C. Wainwright & Co., LLC is disclosed as the associated broker-dealer.
Enveric Biosciences, Inc. (ENVB) Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reports shared beneficial ownership of warrants and shares following a September 17, 2025 letter agreement with the issuer. After that transaction the Reporting Persons may be deemed to beneficially own 266,668 shares each held by Intracoastal (approximately 5.2% of outstanding common stock based on 5,079,612 shares) if certain warrants were exercisable, but as of the close of business on September 24, 2025 each Reporting Person may be deemed to own 19,333 shares (approximately 0.4%) issuable upon exercise of Intracoastal Warrant 3. Intracoastal Warrant 1 and 2 are not exercisable pending shareholder approval and all three warrants contain blocker provisions limiting exercises above 4.99%.
Enveric Biosciences furnished a press release providing a corporate update and announcing financial results for the quarter ended June 30, 2025, which is attached as Exhibit 99.1 to this Current Report on Form 8-K. The filing also includes a machine-readable Interactive XBRL cover page (Exhibit 104). The Form states the press release and related information are furnished, not filed, and therefore are not subject to Section 18 liability or automatically incorporated by reference into future registration statements except by specific reference.
No numerical financial figures or earnings tables are included in the body of the Form 8-K itself; the substantive financial results are contained in the furnished press release. The filing is signed by Chief Executive Officer Joseph Tucker, Ph.D.
FAQ
What is the current stock price of Enveric Biosciences (ENVB)?
What is the market cap of Enveric Biosciences (ENVB)?
